Table 4.
Detailed COVID-19 positive patients characteristics
| Diagnosis | S e x |
A g e |
PS | C-19 diagnosis | Rx (date) | CT (date) | Systemic treatment | RT | RT site | Treatment suspension | Treatment completed | COVID severity | Treatment for COVID-19 | oxygen supplement | Negativization | Death | Smoke | Comorbidities |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cT1c N2 M0 NSCLC treated with radical RT-CHT | M | 75 | 1 | 03/04/20 |
Pos 03/04 |
No | Maintenance durvalumab (VI cicle) | No | No | Definitive | No | Severe | HCQ + L/R + AZT | oxygen mask | No | 03/07/20 | yes | St I COPD, diverticulosis, chronic gastritis |
| Multiple myeloma St. III (ECOG PS 3) | M | 61 | 3 | 03/04/20 | Pos 03/01 | No | First line bortezomib | Palliative RT | 20Gy/5fr C2-C5 + S1-S2 vertebral tract | Definitive | No | Severe | No | oxygen mask | No | 03/06/20 | yes | None |
| pT2 pN2a M0 breast cancer | F | 59 | 0 | 03/05/20 |
Pos. 03/05 |
No | Adjuvant weekly paclitaxel | Adjuvant RT | 50Gy/25 fr on residual left breast parenchima + SIC LN | Temporary at 16 Gy.a. | Yes | Mild | HCQ + L/R + AZT | oxygen mask | 04/02/20 | No | no | Brugada syndrome |
| cT4 N1 M0 NSCLC | M | 79 | 1 | 06/03/20 | 08/03/20 + | No | No | Radical RT | 60 Gy/30 fr R para-hilar lesion + mediastinal 7,10R,5,4R | Definitive (16 Gy) | No | Severe | HCQ + L/R + AZT | oxygen mask | No | 03/16/20 | yes | Arterial hypertension, peripheral obliterant arteriopathy |
| cT2aN3M1c (bone, adrenal gland) NSCLC (ECOG PS 3) | M | 59 | 3 | 03/08/20 |
Neg 03/08 |
No | Atezolizumab (last 31/01) | Palliative RT | 20Gy/4fr T6–8 vertebral tract +8Gy/1fr L1 vertebra + sacrum | Definitive | No | Severe | HCQ + L/R + AZT | oxygen mask | No | 03/14/20 | yes | Myocardial fibrosis, HBV induced hepatitis |
| cT1N3M0 oropharyngeal SCC, p16- | M | 72 | 1 | 03/14/20 |
Pos 03/12 |
Pos 03/13 |
Weekly concomitant cisplatin (4 cycles) | Radical RT-CHT | L palatine tonsil + L cervical LN levels Ib, II e III 69,3Gy/33 fr + bilateral neck 56.1Gy/33fr | Definitive (52.5Gy/25fr) | No | Severe | HCQ + L/R + AZT + tocilizumab | NIV (CPAP) | No | 03/30/20 | yes | Type 2 diabetes |
| rcT3 N2 M0 NSCLC | M | 75 | 1 | 03/16/20 |
Pos 03/20/20 |
Pos 03/18/20 |
No | Radical RT | 52 Gy/26fr + 5Gy/2fr middle lobe lesion+4R lev | No | Yes | Mild | HCQ + L/R + AZT + tocilizumab | oxygen mask | 03/30/20 | No | ex smoker | Arterial hypertension, carotid stenosis, deep venous thrombosis |
| cT4 N1 M0 rectal cancer | M | 83 | 1 | 03/16/20 | Pos 03/15 | Pos 03/18 | No | Neoadjuvant RT | 50,4 Gy/28 fr rectum + pelvic lymph nodes | Definitive | No | Mild | HCQ + L/R + AZT | oxygen mask | 03/30/20 | No | no | benign prostatic hyperplasia |
| cT4aN3bM0 oropharyngeal SCC, concomitant cT4aN0M0 hypopharyngeal SCC | M | 85 | 1 | 03/23/20 |
Pos 03/23 |
Pos 15/04 |
No | Radical RT | 70 Gy/35 fr oro-hypopharynx, cervical esophagus and L cervical LN levels IIa-IV | No | Yes | Severe | HCQ + L/R + AZT | oxygen mask | No | No | ex smoker | chronic ischemic heart disease, aortic aneurysm, MRGE, supraventricular arrhythmia |
| cT3 N2 M0 NSCLC | F | 60 | 0 | 03/23/20 | Pos 03/25 | Pos 03/25 | No | High dose palliative RT | 60 Gy/30 fr R superior lobe and lesion + mediastinal levels 4R, 7, 10R,13R,11R,14R | No | Yes | Mild | HCQ + Symtuza | oxygen mask | 04/14/20 | No | yes | HIV+, HCV +, quantiferon + |
| cT3 N3 M0 NSCLC | M | 61 | 1 | 03/24/20 | Pos 03/26 | Pos 03/24 | No | Radical RT | 60 Gy/30 fr R superior lobe lesion + mediastinal levels 10R, 7, 4R, 2R, | No | Yes | Mild | HCQ + D/R + tocilizumab | oxygen mask | 04/12/20 | No | yes | dyslipidemia, previous prostate cancer |
| cT3 N0 M0 NSCLC | M | 63 | 0 | 03/24/20 | Pos 03/30 | No | Concomitant carboplatin + paclitaxel | Radical RT | 60 Gy/30 fr L pulmonary apex | No | Yes | Mild | HCQ + D/R + AZT | no | 04/06/20 | No | yes | Arterial hypertension, Mitral insufficiency, thyroid goiter, Type 2 diabetes |
| cT1bN0M0 NSCLC (single brain lesion) | M | 69 | 1 | 04/10/20 |
Neg 04/03 |
No | No | Radical dose RT + SRS on M1 | 24 Gy/3 fr single brain lesion and 60 Gy/8 fr L lung superior lobe | No | Yes | Mild | No | no | No | No | yes | Arterial hypertension, previous ictus cerebri, carotid stenosis |
PS Eastern Cooperative Oncology Group Performance Status, C-10 COVID-19, Rx chest radiograph, CT chest CT scan, RT radiation therapy, M male, F female, L left, R right, fr fractions, LN lymph nodes, SIC supra and infraclavicular, HCQ hydroxychloroquine, L/R lopinavir/ritonavir, AZT azithromycin, N norvir, D/R darunavir/ritonavir, COPD Chronic Obstructive Pulmonary Disease
aRestarted after 45 days after replanning